DEA Schedules Opioid Compounds as Controlled Substances

The Drug Enforcement Administration (DEA) announced on March 12, 2024, that it has issued a temporary order to schedule three opioid compounds as controlled substances. This action specifically targets mitragynine pseudoindoxyl and 7-hydroxymitragynine, which are naturally occurring alkaloids found in the kratom plant. The DEA's decision is based on a finding that these substances pose a significant risk of abuse and addiction, aligning with the criteria for scheduling under the Controlled Substances Act. The temporary scheduling will remain in effect for two years, with a possible one-year extension, allowing the agency to gather further data and consider permanent scheduling. This move aims to address the growing concerns surrounding the misuse of kratom-derived compounds, which have been increasingly marketed as dietary supplements and natural remedies. The DEA's order classifies these compounds under Schedule I of the Controlled Substances Act, the most restrictive category, which is reserved for substances with a high potential for abuse, no currently accepted medical use in treatment, and a lack of accepted safety for use under medical supervision. The agency highlighted that kratom has been associated with numerous adverse events, including respiratory depression, seizures, and fatalities, often when combined with other substances. The temporary scheduling is a critical step in preventing the diversion and illicit use of these potent opioid compounds. The DEA's action follows a period of increased scrutiny on kratom products, as regulatory bodies grapple with how to classify and control substances that are readily available to the public but possess significant pharmacological effects. The agency emphasized that this temporary scheduling is a proactive measure to protect public health and safety. The scheduling order will be published in the Federal Register, initiating the formal process for public comment and potential permanent scheduling. This temporary scheduling is a significant development in the ongoing efforts to regulate substances with opioid-like properties and mitigate the public health risks associated with their misuse. The DEA's commitment to addressing the opioid crisis extends to novel psychoactive substances, and this action reflects a broader strategy to control emerging threats. The agency will continue to monitor the evolving landscape of drug abuse and take appropriate actions to safeguard communities. The temporary scheduling of mitragynine pseudoindoxyl and 7-hydroxymitragynine signifies the DEA's intent to apply existing drug control frameworks to substances derived from natural sources that exhibit dangerous pharmacological profiles. This measure is expected to impact the availability and distribution of products containing these compounds, potentially leading to increased enforcement actions against those who distribute or possess them without proper authorization. The DEA's announcement underscores the complexity of regulating substances that exist in a gray area between natural products and controlled drugs, and this temporary scheduling provides an immediate mechanism for control while further scientific and regulatory evaluation takes place. The agency's decision is informed by scientific evidence and a commitment to public health, aiming to prevent further harm associated with the misuse of these opioid compounds.